Grant Recipients 2009 - current

Funded Applications

2017

2016 

2015

2014

2013

2012

2011

2010

2009

Total Applications Received

297

 199

145

185

196

166

159

156

174

Success Rate

18%

 24%

33%

21%

13%

26%

27%

31%

29%

Al & Val Rosenstrauss Fellowship Recipients

Dr Sylvia Gustin

Dr Sylvia Gustin: 2017 Recipient

 

Dr Shelley Gorman

Dr Shelley Gorman: 2016 Recipient

 

Dr Graeme Polglase

Dr Graeme Polglase: 2012 Recipient

PhD Scholarship Recipients

Ariel Goh: Second year PhD

PhD student 

Seamus Thomson: Second year PhD

PhD student

Stephanie Yee: Second year PhD

PhD

 

Our Impact

The testimonials below illustrate the impact of the Foundation's funding on he careers of two researchers, and the subsequent advancements achieved in their chosen field of medical research.

Asthma research ~ Prof Phil Hanbro

I was appointed as a junior academic at the University of Newcastle in November 1999. My first tasks were to establish my teaching and develop my own research program in lung diseases. To do this, I needed to secure funding so that I could establish a research platform.

So I applied for many different grants and after many disappointments, I received a real break when in 2002, I was awarded my first research grant of $16,000 and was awarded the 'Leo Dintenfass Plaque' from the Rebecca L. Cooper Medical Research Foundation.

This seeding grant really kick started my research, allowing me to undertake several projects and produce preliminary data. These data were ultimately used in large grant applications and from this, my group grew from strength to strength.

Over the years, I have been fortunate enough to receive several grants from the Rebecca Cooper Foundation, each of which has enabled the commencement of new phases of my research and has allowed my program to mature and diversify.

Indeed, with an investment from the Foundation to date totalling $116,000, made up of research grants and phd scholarships, I have been successful as a primary or co-Chief Investigator in obtaining $3.7 million in project grants and $1.5 million in equipment and infrastructure funding.

This represents a 45-fold magnitude of the initial seed funding and includes 5 NHMRC project and 1 ARC discovery grants. This investment has also translated into the training of younger scientists which to date has resulted in 3 phd and 8 Honours students having graduated from my lab, with another 6 phd and 1 Honours student on the way.
It was most satisfying to see one of my former phd students, Dr Jay Horvat, also get a start from the Foundation with his first grant in 2009. It is very rewarding to see the cycle repeat itself.

We have made excellent progress with the assistance of this funding. My group has made important and novel observations of the pathogenesis of bacterial and viral infections and how they differentially affect the development and exacerbation of asthma.

We showed for the first time, that the age of first infection and the timing of infection relative to allergic sensitisation, play pivotal roles in determining the effects of chlamydial infection on asthma. We also showed that the nature of infection is important and that Chlamydia and Haemophilus infections promote or modify asthma, whereas Streptococcus pneumoniae is protective against asthma.
This identifies new therapeutic opportunities for asthma where we can either target (Chlamydia, Haemophilus) or use (S. Pneumoniae) bacteria for the prevention and treatment of asthma.

We have produced 23 publications in the last 5 years on these studies and several more are under review. Therefore, and most importantly, the seed funding from the Foundation has been invaluable in establishing my research and my group and has translated into significant outcomes for lung disease and human health.
None of these outcomes would have been possible without this initial funding from the Foundation.

I would like to sincerely thank the Foundation and look forward to a very promising future and an increasingly productive relationship with the Rebecca L. Cooper Medical Research Foundation.

 

Schizophrenia research Prof Brian Dean

In 1987 I moved from the Department of Diabetes and Endocrinology at the Royal Melbourne Hospital to the Mental Health Research Institute.  One reason for this move was to begin studies for my PhD. 

My chosen area of study was to understand the biochemical changes that were causing the symptoms of schizophrenia.  My premise was that schizophrenia, like any other disease, must have an understandable cause and in identifying the cause we would be able to devise improved treatments for the disorder.  As my decision to change research direction became known the general view was that I had entered a field of research endeavour that was the graveyard of many research careers. 

My initial efforts to raise funds to support my research certainly seemed to confirm the idea that funding biochemical based research into schizophrenia was not high on the agenda of many funding agencies.  In 1988 I first became aware of the Rebecca L. Cooper Medical Research Foundation and that they had made schizophrenia a special priority for funding.  I immediately prepared an application for equipment funding.  To my great pleasure this application was funded and I attended my first ‘Foundation Dinner’ in 1989 and collected a cheque that enabled the purchase of a scintillation counter, a critical piece of laboratory equipment.  Up until that funding was available, I had to travel around Melbourne begging any available time on the equipment in other Laboratories. 
More importantly, one of the critical steps that a junior researcher makes on the road to an independent career is to raise funding in support of their research.  Indeed, this application was the foundation stone to the establishment of my own Laboratory at the Mental Health Research Institute. 

This Laboratory subsequently became known as the Rebecca L. Cooper Research Laboratories and has now published over 130 peer reviewed papers and has had successes in raising competitive funding from many funding bodies, including the National Health and Medical Research Council and the National Institutes of Health in the USA. 

Two decades later I continue my research into the causes of schizophrenia and I am pleased to say the ‘Foundation’ continues to support such medical research.  It is apparent that they still support junior researchers in the beginning of their careers and help them realise their research dreams.

  

‚Äč